Spots Global Cancer Trial Database for Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Official Title: Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma
Study ID: NCT01216826
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to determine the Everolimus aim response in children and adolescents with refractory or relapsed osteosarcoma. The aim response is defined as complete or partial response (according to RECIST criteria) for at least 4 weeks, or stable disease for at least 12 weeks.
Detailed Description:
Keywords
Eligibility
Minimum Age:
Eligible Ages: CHILD, ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hospital Santa Marcelina, Sao Paulo, SP, Brazil
Contact Details
Name: Sidnei Epelman, MD
Affiliation: Hospital Santa Marcelina
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
